Pan-Tumor IHC Screen Suggests FAP Target is Attractive for PTRT
A pan-tumor IHC screen identified high fibroblast activating protein (FAP) expression in multiple tumor types that correlated with in vitro
Read moreA pan-tumor IHC screen identified high fibroblast activating protein (FAP) expression in multiple tumor types that correlated with in vitro
Read moreKite Pharma, a Gilead Company, announced on Friday that the U.S. FDA has granted approval for CAR T-cell therapy Tecartus®
Read moreGenmab A/S and Seagen Inc. revealed that the first and only approved antibody-drug conjugate (ADC) known as TIVDAKâ„¢ (tisotumab vedotin-tftv),
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreThe NHS-Galleri Trial is being launched to evaluate whether a blood test may help identify cancer earlier when combined with
Read moreAmgen’s first-in-class KRAS G12C inhibitor LumykrasTM (sotorasib) has been granted Conditional Marketing Authorisation by the Medicines and Healthcare products Regulatory
Read moreArvinas and Pfizer have announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera)
Read moreThe CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A EUCODIS Bioscience Case Study
Read moreQIAGEN officially confirmed a global cooperation agreement with Sysmex Corporation for the development and commercialization of cancer companion diagnostics, leveraging
Read moreNucleai and Merck KGaA will collaborate utilizing Nucleai’s AI-powered platform to develop pathology-based biomarkers as companion diagnostics. Nucleai, a precision
Read more